Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis

Rev Soc Bras Med Trop. 2016 Nov-Dec;49(6):774-776. doi: 10.1590/0037-8682-0213-2016.

Abstract

Introduction:: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity.

Methods: Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals.

Results: The technique is described in detail sufficient to enable replication.

Conclusions:: The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings.

MeSH terms

  • Antiprotozoal Agents / administration & dosage*
  • Humans
  • Injections, Intralesional / standards
  • Leishmaniasis, Cutaneous / drug therapy*
  • Meglumine / administration & dosage*
  • Meglumine Antimoniate
  • Organometallic Compounds / administration & dosage*

Substances

  • Antiprotozoal Agents
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate